Drug Profile
Glucagon-like peptide-1 analogue - CellMed
Alternative Names: CM-3; CM3 (second-generation GLP-1) - CellMed; CM3 protein - CellMed; CM3.1; CM3.1-AC100; CM31; Glucagon-like peptide (GLP)-1 analogues for diabetes - CellMed/AstraZenecaLatest Information Update: 10 Nov 2021
Price :
$50
*
At a glance
- Originator CellMed
- Class Glucagon-like peptides; Hormones
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 01 Dec 2013 Discontinued - Phase-I for Obesity in Germany (SC)
- 01 Dec 2013 Discontinued - Phase-I for Type-2 diabetes mellitus in Germany (SC)